Pfizer’s new RA clears phase III

Tuesday, March 8, 2011 10:51 AM

Pfizer has reported data from its phase III trial of its oral JAK inhibitor tofacitinib, which underwent a name change from tasocitinib. The drug hit its primary endpoint for statistical significance among patients with rheumatoid arthritis. The experimental therapy, one of Pfizer's biggest late-stage prospects, was shown to improve symptoms of RA. Full data will be forthcoming.

The drug targets the intracellular signaling pathways—rather than extracellular targets—that operate as hubs in the inflammatory cytokine network. Analysts have been awaiting the results of its potential for RA treatment as well as for a full slate of other inflammatory conditions.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs